The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More
News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More
Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million. Neurogene is developing approaches and treatments which it hopes will address the limitations of conventional… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK… Read More
News round-up for 28 Oct – 1 Nov by DDW Senior Digital Content Editor Diana Spencer. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and… Read More
News round-up for 21-25 October by DDW Senior Digital Content Editor Diana Spencer. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week… Read More
The University of Texas MD Anderson Cancer Center has been awarded $20 million to strengthen neurodegeneration research. The donation was awarded to the Belfer Neurodegeneration Consortium (BNDC), which aims to develop five new medicines for Alzheimer’s disease and related disorders over the next 10 years, with… Read More
Arena BioWorks has launched as a biomedical research institute with a stated mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics. Arena BioWorks describes itself as a dual-purpose entity aimed at achieving social good and… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More
News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More
It’s not easy being the new kid on the block. DDW’s Diana Spencer speaks to the CEOs of two drug discovery start-ups to find out how they have overcome the challenges of launching a new company in a competitive market. It’s a challenging time to launch… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The theme of DDW’s news review this week is money. Although Clarivate has reported a recent… Read More
News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer. The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and… Read More
The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence,… Read More
Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors. However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from… Read More
